Inhibrx Biosciences, Inc.
ozekibart
Ewing Sarcoma
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews ozekibart for Ewing Sarcoma around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 12h ago
“We plan to meet with the FDA to discuss accelerated approval for Ewing Sarcoma and fourth line colorectal cancer in the second half of 2026.”